Novo Nordisk A/S (NOVC.DE) XETRA
91.40
-1.85(-1.98%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Novo Nordisk A/S
Sector
Healthcare
Industry
Biotechnology
Employees
59337
First IPO Date
June 07, 2001
Key Executives
| Name | Title | Pay | Year Born |
| Lars Fruergaard Jorgensen | Pres, Chief Executive Officer & Member of Management Board | 4.61M | 1966 |
| Martin Holst Lange | Executive Vice President of Devel. & Member of the Management Board | 1.74M | 1970 |
| Marcus Schindler | EVice President of Research & Early Devel., Chief Scientific Officer & Member of the Management Board | 1.74M | 1966 |
| Camilla Sylvest | Executive Vice President of Commercial Strategy & Corporation Affairs and Member of the Management Board | 1.8M | 1972 |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board | 1.83M | 1971 |
| Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality & IT and Member of the Management Board | 1.84M | 1970 |
| Douglas J. Langa | Executive Vice President of North America Operations & Member of Management Board | 0 | 1966 |
| Ludovic Helfgott | Executive Vice President, Head of Rare Disease & Member of Management Board | 0 | 1974 |
| Maziar Mike Doustdar | Executive Vice President of International Operations & Member of the Management Board | 0 | 1970 |
| Tania Sabroe | Executive Vice President of Global People & Organisation and Member of Management Board | 0 | N/A |
Description
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
